Rabbit Recombinant Monoclonal EIF2A antibody - conjugated to HRP. Suitable for WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
WB | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/5000 | Notes - |
Select an associated product type
Functions in the early steps of protein synthesis of a small number of specific mRNAs. Acts by directing the binding of methionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF-2 complex, it binds methionyl-tRNAi to 40S subunits in a codon-dependent manner, whereas the eIF-2 complex binds methionyl-tRNAi to 40S subunits in a GTP-dependent manner.
CDA02, MSTP004, MSTP089, EIF2A, Eukaryotic translation initiation factor 2A, eIF-2A, 65 kDa eukaryotic translation initiation factor 2A
Rabbit Recombinant Monoclonal EIF2A antibody - conjugated to HRP. Suitable for WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The eIF2A also referred to as eukaryotic translation initiation factor 2A is a protein involved in the initiation of mRNA translation. The eIF2A protein is distinct from eIF2α despite the similarity in their names. Its molecular weight is approximately 65 kDa. Expression of eIF2A occurs mainly in the cytoplasm of cells where it participates in the protein synthesis process. eIF2A functions as a mediator that targets the initiator methionylated-tRNA to the small ribosomal subunit in a manner independent from eIF2 complex.
EIF2A impacts the translation mechanism by facilitating the binding of Met-tRNAi to the ribosome under particular conditions especially during stress responses where canonical eIF2 might be inhibited. It operates independently from the larger eIF2 complex which also includes eIF2β and eIF2γ subunits. This independent activity allows eIF2A to serve as a backup mechanism for translation initiation when the normal pathway is impaired.
Translation regulation involves interaction with cellular stress pathways and the integrated stress response (ISR). eIF2A operates within pathways that respond to physiological stresses such as nutrient deprivation and oxidative stress which trigger alterations in protein synthesis rates. eIF2A is related to the eIF2 kinase which phosphorylates the α subunit of eIF2 leading to a general reduction in translation initiation under stress allowing selective translation of stress-response proteins.
Irregularities in eIF2A function link to neurodegenerative diseases such as Alzheimer's disease and metabolic disorders like diabetes. These conditions often involve disruptions in the stress response pathways where eIF2A participates. The protein participates with others like PERK a kinase that phosphorylates eIF2α under endoplasmic reticulum stress contributing to disease-related changes in protein synthesis. By modulating translation under stress eIF2A becomes significant in these pathological contexts.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab215342 was shown to specifically react with eIF2A in wild-type HAP1 cells as signal was lost in EIF2A (eIF2A) knockout cells. Wild-type and EIF2A (eIF2A) knockout samples were subjected to SDS-PAGE. ab215342 and Alexa Fluor® 680 Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/5000 dilution and 1/1000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.
All lanes: Western blot - HRP Anti-eIF2A antibody [EPR11042] (ab215342) at 1/5000 dilution
Lane 1: Wild-type HAP1 whole cell lysate at 20 µg
Lane 2: EIF2A (eIF2A) knockout HAP1 whole cell lysate at 20 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 65 kDa
Observed band size: 65 kDa
Exposure time: 8min
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab215342 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-eIF2A antibody [EPR11042] (ab215342) at 1/5000 dilution
Lane 1: MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate at 10 µg
Lane 2: Ramos (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg
Lane 3: HAP1 WT at 20 µg
Lane 4: eIF2A knockout HAP1 at 20 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 65 kDa
Observed band size: 65 kDa
Exposure time: 8min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com